Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials.

[1]  E. Rutgers,et al.  Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials , 2015, The Lancet.

[2]  Q. Mei,et al.  Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer , 2015, Scientific Reports.

[3]  R. Laing,et al.  Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). , 2015, European urology.

[4]  E. Lion,et al.  Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy , 2015, Oncoimmunology.

[5]  K. Blackwell,et al.  Routine use of zoledronic acid in early-stage breast cancer. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  L. Fu,et al.  Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review. , 2015, Critical reviews in oncology/hematology.

[7]  G. Colditz,et al.  Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma , 2015, Leukemia & lymphoma.

[8]  Kurt Miller,et al.  Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). , 2015, European urology.

[9]  R. Greil,et al.  Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  E. Adams,et al.  Sensing of Pyrophosphate Metabolites by Vγ9Vδ2 T Cells , 2015, Front. Immunol..

[11]  G. Calin,et al.  Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer , 2015, Clinical Cancer Research.

[12]  T. Yuen,et al.  Questioning the association between bisphosphonates and atypical femoral fractures , 2015, Annals of the New York Academy of Sciences.

[13]  Naveid A Ali,et al.  Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. , 2015, Cancer discovery.

[14]  T. Yuen,et al.  Bisphosphonates inactivate human EGFRs to exert antitumor actions , 2014, Proceedings of the National Academy of Sciences.

[15]  J. Buckwalter,et al.  Osteoclast inhibition impairs chondrosarcoma growth and bone destruction , 2014, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[16]  Ling-Ling Zhu,et al.  Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer , 2014, Proceedings of the National Academy of Sciences.

[17]  Yoshimasa Tanaka,et al.  Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol , 2014, Journal of Translational Medicine.

[18]  E. Oldfield,et al.  A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin , 2014, Science Translational Medicine.

[19]  Youwen Zhou,et al.  Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. , 2014, The Journal of investigative dermatology.

[20]  S. Zappavigna,et al.  Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: A comparative analysis through time lapse video-microscopy technique , 2014, Cancer biology & therapy.

[21]  S. Cummings,et al.  Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. , 2014, JAMA internal medicine.

[22]  Lu Gao,et al.  Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. , 2014, Cancer letters.

[23]  Diana Boraschi,et al.  From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation , 2014, Front. Immunol..

[24]  B. Delahunt,et al.  Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. , 2014, The Lancet. Oncology.

[25]  S. Carr,et al.  A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages , 2014, Nature Cell Biology.

[26]  E. Higashihara,et al.  Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial. , 2014, Anticancer research.

[27]  D. Cameron,et al.  Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. , 2014, The Lancet. Oncology.

[28]  T. Yamanaka,et al.  Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group , 2014, Cancer science.

[29]  F. Luo,et al.  Recent advances in bone-targeted therapies of metastatic prostate cancer. , 2014, Cancer treatment reviews.

[30]  R. Schwendener,et al.  Macrophage Depletion by Free Bisphosphonates and Zoledronate-Loaded Red Blood Cells , 2014, PloS one.

[31]  B. Müller,et al.  Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature. , 2014, Swiss medical weekly.

[32]  Tetsuro Ohba,et al.  Pleiotropic effects of bisphosphonates on osteosarcoma. , 2014, Bone.

[33]  Tetsuro Ohba,et al.  Bisphosphonates Inhibit Osteosarcoma‐Mediated Osteolysis Via Attenuation of Tumor Expression of MCP‐1 and RANKL , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  H. Putter,et al.  Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  F. Saad,et al.  Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  I. Holen,et al.  Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo , 2014, Clinical Cancer Research.

[37]  G. Pond,et al.  A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events , 2014, Breast Cancer Research and Treatment.

[38]  Y. Nie,et al.  Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression , 2014, Hepatology.

[39]  M. Lux,et al.  FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients , 2014, BMC Cancer.

[40]  S. Fox,et al.  Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the “biological window therapy” , 2014, Breast Cancer Research and Treatment.

[41]  M. Carducci,et al.  Bone-targeting agents in prostate cancer , 2014, Cancer and Metastasis Reviews.

[42]  J. Eastham,et al.  Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid. , 2014, European urology.

[43]  K. Hood,et al.  Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. , 2014, The Lancet. Oncology.

[44]  F. Cornelis,et al.  Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy. , 2014, Bone.

[45]  D. Heymann,et al.  Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration , 2014, BMC Cancer.

[46]  R. Chan,et al.  Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies , 2014, Supportive Care in Cancer.

[47]  S. Barni,et al.  Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey , 2013, PloS one.

[48]  G. Morgan,et al.  The impact of response on bone-directed therapy in patients with multiple myeloma. , 2013, Blood.

[49]  A. Schneeweiss,et al.  German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  S. Boonen,et al.  Renal safety in patients treated with bisphosphonates for osteoporosis: A review , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[51]  S. Horie,et al.  Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study. , 2013, Anticancer research.

[52]  G. Morgan,et al.  Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment , 2013, Clinical Cancer Research.

[53]  Z. Weng,et al.  Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases , 2013, Medical Oncology.

[54]  R. Goldsby,et al.  Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. , 2013, European journal of cancer.

[55]  G. Morgan,et al.  International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Wun-Jae Kim,et al.  BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages. , 2013, Cancer research.

[57]  T. Fehm,et al.  Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial , 2013, BMC Cancer.

[58]  D. Amadori,et al.  Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. , 2013, The Lancet. Oncology.

[59]  C. Laverdière,et al.  Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia , 2013, Pediatric blood & cancer.

[60]  J. Shah,et al.  Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. , 2013, Clinical lymphoma, myeloma & leukemia.

[61]  K. Hirata,et al.  Zoledronic acid but not somatostatin analogs exerts anti‐tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration‐resistant prostate cancer , 2013, The Prostate.

[62]  S. Cross,et al.  Neoadjuvant Chemotherapy with or without Zoledronic Acid in Early Breast Cancer—A Randomized Biomarker Pilot Study , 2013, Clinical Cancer Research.

[63]  G. Salzano,et al.  Bisphosphonates and Cancer: What Opportunities from Nanotechnology? , 2013, Journal of drug delivery.

[64]  A. Avilés,et al.  Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. , 2013, Current oncology.

[65]  B. Klein,et al.  Anti‐tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside , 2013, British journal of haematology.

[66]  P. Kosmidis,et al.  Treatment of bone metastases before the onset of pain , 2013, International Journal of Clinical Oncology.

[67]  S. Noguchi,et al.  Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial , 2013, International Journal of Clinical Oncology.

[68]  C. Gialeli,et al.  Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. , 2012, Biochimica et biophysica acta.

[69]  B. Delahunt,et al.  Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. , 2012, The Lancet. Oncology.

[70]  B. Delahunt,et al.  Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[71]  O. Dalesio,et al.  Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). , 2012, European journal of cancer.

[72]  Zygmunt Gryczynski,et al.  Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. , 2012, Biomaterials.

[73]  T. Fehm,et al.  Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  A. Russo,et al.  Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells , 2012, Journal of cellular and molecular medicine.

[75]  G. Scagliotti,et al.  Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  G. Morgan,et al.  Effects of bone-targeted agents on cancer progression and mortality. , 2012, Journal of the National Cancer Institute.

[77]  E. Perez,et al.  Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. , 2012, The Lancet. Oncology.

[78]  Zhi-ren Zhang,et al.  Macrophages in Tumor Microenvironments and the Progression of Tumors , 2012, Clinical & developmental immunology.

[79]  G. Morgan,et al.  Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. , 2012, Blood.

[80]  R. Aft,et al.  Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer , 2012, British Journal of Cancer.

[81]  B. Djulbegovic,et al.  Bisphosphonates in multiple myeloma. , 2010, The Cochrane database of systematic reviews.

[82]  J. McGuirk,et al.  Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation , 2012, Clinical transplantation.

[83]  F. Saad,et al.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  A. Mishra,et al.  Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[85]  M. Imano,et al.  Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. , 2012, Toxicology and applied pharmacology.

[86]  J. Becker,et al.  Tumor-promoting Versus Tumor-antagonizing Roles of &ggr;&dgr; T Cells in Cancer Immunotherapy: Results From a Prospective Phase I/II Trial , 2012, Journal of immunotherapy.

[87]  T. Ichikawa,et al.  Additive effect of zoledronic acid on serum prostate‐specific antigen changes for hormone‐sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade , 2012, International journal of urology : official journal of the Japanese Urological Association.

[88]  W. Jahnke,et al.  The chemistry of bisphosphonates: from antiscaling agents to clinical therapeutics. , 2012, Anti-cancer agents in medicinal chemistry.

[89]  P. Clézardin.  Potential anticancer properties of bisphosphonates: insights from preclinical studies. , 2012, Anti-cancer agents in medicinal chemistry.

[90]  Z. Shao,et al.  The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. , 2012, European journal of cancer.

[91]  R. Schwendener,et al.  Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors , 2012, BMC Cancer.

[92]  I. Holen,et al.  Tumour macrophages as potential targets of bisphosphonates , 2011, Journal of Translational Medicine.

[93]  W. Gregory,et al.  Breast-cancer adjuvant therapy with zoledronic acid. , 2011, The New England journal of medicine.

[94]  R. Kimmig,et al.  Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. , 2011, Anticancer research.

[95]  Y. Iwamoto,et al.  Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. , 2011, The American journal of pathology.

[96]  S. Groshen,et al.  A phase I study of zoledronic acid and low‐dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study , 2011, Pediatric blood & cancer.

[97]  R. Greil,et al.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. , 2011, The Lancet. Oncology.

[98]  P. Miller.  The kidney and bisphosphonates. , 2011, Bone.

[99]  J. Lang,et al.  Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma , 2011, Cancer Immunology, Immunotherapy.

[100]  K. Michaëlsson,et al.  Bisphosphonate use and atypical fractures of the femoral shaft. , 2011, The New England journal of medicine.

[101]  P. Gobbi,et al.  Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study , 2011, Leukemia & lymphoma.

[102]  J. Healey,et al.  Addition of pamidronate to chemotherapy for the treatment of osteosarcoma , 2011, Cancer.

[103]  Y. Huang,et al.  Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases. , 2011, European journal of cancer.

[104]  Hisao Ito,et al.  Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines. , 2011, Oncology reports.

[105]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[106]  V. Castronovo,et al.  Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. , 2011, Bone.

[107]  Si Sun,et al.  Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid , 2011, BMC Cancer.

[108]  J. Hardes,et al.  Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78 , 2011, International Orthopaedics.

[109]  E. Francini,et al.  Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer , 2011, International Journal of Clinical Oncology.

[110]  G. Morgan,et al.  First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial , 2010, The Lancet.

[111]  A. Lipton,et al.  Anticancer Properties of Zoledronic Acid , 2010, Cancer investigation.

[112]  P. Fayers,et al.  Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. , 2010, The Lancet. Oncology.

[113]  O. Delattre,et al.  Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. , 2010, Cancer research.

[114]  J. Ragaz,et al.  Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance , 2010, Breast Cancer Research and Treatment.

[115]  P. Picci,et al.  Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone , 2010, BMC Cancer.

[116]  M. Todaro,et al.  In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low‐dose interleukin‐2 for immunotherapy of advanced breast cancer patients , 2010, Clinical and experimental immunology.

[117]  M. Nimwegen,et al.  Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma , 2010, British Journal of Cancer.

[118]  C. Cole,et al.  Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL) , 2010, Pediatric blood & cancer.

[119]  J. Ingle,et al.  A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. , 2010, Bone.

[120]  S. Saussez,et al.  Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases , 2010, Journal of Cancer Research and Clinical Oncology.

[121]  E. Shane.  Evolving data about subtrochanteric fractures and bisphosphonates. , 2010, The New England journal of medicine.

[122]  M. Ellis,et al.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. , 2010, The Lancet. Oncology.

[123]  H. Sommer,et al.  Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. , 2010, Anticancer research.

[124]  C. Finucane,et al.  188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases. , 2010, Bioconjugate chemistry.

[125]  N. Watts,et al.  Long-term use of bisphosphonates in osteoporosis. , 2010, The Journal of clinical endocrinology and metabolism.

[126]  M. Zaghloul,et al.  A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer , 2010, International Journal of Clinical Oncology.

[127]  R E Coleman,et al.  The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer , 2010, British Journal of Cancer.

[128]  R. Weichselbaum,et al.  Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. , 2010, Cancer research.

[129]  T. Powles,et al.  Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. , 2010, European journal of cancer.

[130]  P. Musiani,et al.  Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway , 2009, Journal of cellular and molecular medicine.

[131]  M. Tiemann,et al.  The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation , 2010, International journal of cancer.

[132]  D. Ribatti,et al.  Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. , 2010, European journal of cancer.

[133]  J. Pelkonen,et al.  The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. , 2009, Bone.

[134]  P. Heras,et al.  Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. , 2009, European journal of cancer care.

[135]  M. Parmar,et al.  Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials , 2009, The Lancet. Oncology.

[136]  Kenshi Suzuki,et al.  Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. , 2009, Experimental hematology.

[137]  R. Greil,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[138]  H. Nagawa,et al.  Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. , 2009, The Journal of surgical research.

[139]  F. Schuetz,et al.  Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[140]  M. Boccadoro,et al.  A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma , 2008, Cancer.

[141]  B. Clarke,et al.  Bisphosphonates: mechanism of action and role in clinical practice. , 2008, Mayo Clinic proceedings.

[142]  R. Greil,et al.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. , 2008, The Lancet. Oncology.

[143]  R. Coleman.  Risks and benefits of bisphosphonates , 2008, British Journal of Cancer.

[144]  H. Knüpfer,et al.  sIL‐6R: more than an agonist? , 2008, Immunology and cell biology.

[145]  J. Bergh,et al.  Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer , 2008, Acta oncologica.

[146]  Y. Aizawa,et al.  Anti-tumor cytotoxicity of γδ T cells expanded from peripheral blood cells of patients with myeloma and lymphoma , 2008, Medical oncology.

[147]  C. Agrati,et al.  In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients , 2008, Cancer Immunology and Immunotherapy.

[148]  G. Hortobagyi,et al.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[149]  D. Ribatti,et al.  Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma , 2007, Molecular Cancer Therapeutics.

[150]  D. Kimmel.  Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates , 2007, Journal of dental research.

[151]  S. Karagiannis,et al.  Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. , 2007, European journal of cancer care.

[152]  F. Saad,et al.  Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. , 2007, Clinical genitourinary cancer.

[153]  M. Eberl,et al.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. , 2007, Cancer research.

[154]  D. Marin,et al.  Dual inhibition of ras and bcr‐abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission , 2007, British journal of haematology.

[155]  Tomoaki Tanaka,et al.  Palliative Treatment of Bone Metastases in Hormone-Refractory Prostate Cancer: Effects of Pamidronate on the Carboxyterminal Telopeptide of Type-I Collagen Level in Patients with Increasing Prostate-Specific Antigen Levels , 2007, Urologia Internationalis.

[156]  M. Taniwaki,et al.  Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. , 2007, Biochemical and biophysical research communications.

[157]  S. Chevalier,et al.  Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. , 2007, Biochemical pharmacology.

[158]  A. Avilés,et al.  Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma , 2007, Medical oncology.

[159]  M. Rogers,et al.  Recent advances in understanding the mechanism of action of bisphosphonates. , 2006, Current opinion in pharmacology.

[160]  I. Holen,et al.  Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates , 2006, Nature Clinical Practice Oncology.

[161]  M. Varettoni,et al.  Zoledronic acid down‐regulates adhesion molecules of bone marrow stromal cells in multiple myeloma , 2005, Cancer.

[162]  M. Boccadoro,et al.  Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma , 2005, Leukemia.

[163]  A. Sewell,et al.  The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins , 2005, Clinical and experimental immunology.

[164]  T. Powles,et al.  Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] , 2006, Breast Cancer Research.

[165]  C. Blomqvist,et al.  Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer , 2005, Breast Cancer Research and Treatment.

[166]  L. Rosen,et al.  Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion , 2004, Cancer.

[167]  Masahiro Inoue,et al.  An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. , 2004, The Journal of clinical investigation.

[168]  C. Blomqvist,et al.  Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients , 2004, Acta oncologica.

[169]  G. Oades,et al.  Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation , 2004, BJU international.

[170]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[171]  D. Tripathy,et al.  Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[172]  D. Tripathy,et al.  Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies , 2004, British Journal of Cancer.

[173]  M. Kamphuis,et al.  Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. , 2003, Blood.

[174]  A. Howell,et al.  Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma , 2003, Cancer.

[175]  P. Musto,et al.  Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. , 2003 .

[176]  A. Bottomley,et al.  Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiograp , 2003, International journal of radiation oncology, biology, physics.

[177]  M. Lichinitser,et al.  Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[178]  G. Avvisati,et al.  Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[179]  G. De Libero,et al.  Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells , 2003, The Journal of experimental medicine.

[180]  J. Goldman,et al.  Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin‐6 and β2‐microglobulin in multiple myeloma , 2003, European journal of haematology.

[181]  T. Powles,et al.  Extended Safety Profile of Oral Clodronate After Long-Term Use in Primary Breast Cancer Patients , 2003, Drug safety.

[182]  E. Thiel,et al.  Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  A. Hellmann,et al.  Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[184]  J. Kanis,et al.  Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myeloma , 2001, British journal of haematology.

[185]  E. Terpos,et al.  Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma , 2000, European journal of haematology.

[186]  G. Hortobagyi,et al.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.

[187]  E. Siris,et al.  Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. , 1980, The New England journal of medicine.